Presentation is loading. Please wait.

Presentation is loading. Please wait.

The Pharmacist’s Role in Drug Quality Surveillance: Perspectives from FDA’s Drug Quality Reporting System The Pharmacist’s Role in Drug Product Quality.

Published byShakira Fuson Modified over 10 years ago

Similar presentations

Presentation on theme: "The Pharmacist’s Role in Drug Quality Surveillance: Perspectives from FDA’s Drug Quality Reporting System The Pharmacist’s Role in Drug Product Quality."— Presentation transcript:

1

2

3 The Pharmacist’s Role in Drug Quality Surveillance: Perspectives from FDA’s Drug Quality Reporting System The Pharmacist’s Role in Drug Product Quality Surveillance: Perspectives from FDA’s Drug Quality Reporting System Vaiyapuri Subramaniam, Pharm.D., FASHP Ralph Jay Schmid, CSO Roger Gregorio, CSO Food and Drug Administration U.S.A.

4 Drug Quality Reporting System (DQRS) Division of Rx Drug Compliance and Surveillance

5 DQRS Background 1971 - 1988 Drug Product Problem Reporting Program (DPPR) 1988 - Present USP Drug Product Problem Reporting Program (USP Program terminated August 31, 2000) 1988 - 1993 Drug Quality Reporting System (DQRS) 1993 - Present MedWatch Program

6 Program Objectives Rapidly identify significant health hazards Detect industry problems and trends Operate a centralized reporting system

7 PMST Responsibilities Screen all reports –Potential Health Hazard Triage (USP reports) –ADEs –Biologics –Foods –Devices

8 Responsibilities (Cont’d) Evaluation of Reports Collect and Verify Information –Contact reporter –Contact CDER review division Search Information Sources –DQRS database, DPS surveys, response letters –Reference materials, e.g., Facts and Comparisons Classification

9 Classification of Reports Priority 1 - Imminent or serious health hazard Priority 2 - Potentially significant CGMP Problems Priority 3 - Routine follow-up

10 CDER Interaction Office of Post-marketing DrugRisk Assessment (OPDRA) Review divisions TIACC GWQAP

11 Primary Users of the DQRS Database District Offices Prepare for GMP Inspection TIACC Investigating therapeutic failures Drug Survey Identify drug Program candidates Office of Identify problem Compliance firms/products USP Monograph

12 Source of DQRS Reports FY-00

13 Source of DQRS Reports FY-01

14 Total DQRS Reports Received USP vs MedWatch USP program terminated August 31, 2000

15 DQRS Reports Resulting In Recalls/Market Withdrawals Recall Classes FY-96 to FY-01

16 Recalls/Market Withdrawals Resulting from DQRS Reports FY-96 to FY-01

17 Corrections Resulting from DQRS FY-96 thru FY-01

18 DQRS Primary Defects Reported FY-00

19 DQRS Primary Defects Reported FY - 01

Download ppt "The Pharmacist’s Role in Drug Quality Surveillance: Perspectives from FDA’s Drug Quality Reporting System The Pharmacist’s Role in Drug Product Quality."

Similar presentations

FDA Medical Device Update

FDA Medical Device Update
What FDA Looks for When Inspecting IRBs and Sponsors Marian J. Serge Nurse Consultant Division of Bioresearch Monitoring Office of Compliance Center for.

What FDA Looks for When Inspecting IRBs and Sponsors Marian J. Serge Nurse Consultant Division of Bioresearch Monitoring Office of Compliance Center for.
Investigating Foodborne Disease Outbreaks: The CDC Perspective Ian Williams, PhD, MS Chief, Outbreak Response and Prevention Branch Division of Foodborne,

Investigating Foodborne Disease Outbreaks: The CDC Perspective Ian Williams, PhD, MS Chief, Outbreak Response and Prevention Branch Division of Foodborne,
What’s New in the FDA’s Pharmaceutical Inspectorate and Risk Based Systems Inspection Rick Perlman Chair Food, Drug, and Cosmetic Division ASQ.

What’s New in the FDA’s Pharmaceutical Inspectorate and Risk Based Systems Inspection Rick Perlman Chair Food, Drug, and Cosmetic Division ASQ.
Focus on Quality FDA Initiative: June 11, 2013 Francisco Vicenty

Focus on Quality FDA Initiative: June 11, 2013 Francisco Vicenty
Pharmaceutical Development and Review Process Rev. 10/21/2014 APGO Interaction with Industry: A Medical Student Guide.

Pharmaceutical Development and Review Process Rev. 10/21/2014 APGO Interaction with Industry: A Medical Student Guide.
Vernon D. Toelle, Ph.D. Team Leader Pre-Market Compliance and Administrative Actions Team (BIMO Team) Overview of CVM Bioresearch Monitoring.

Vernon D. Toelle, Ph.D. Team Leader Pre-Market Compliance and Administrative Actions Team (BIMO Team) Overview of CVM Bioresearch Monitoring.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
FIELD COMPLIANCE UPDATE CDR Thomas R. Berry, RPh FDA, Investigator RAL-RP / ATL-DO.

FIELD COMPLIANCE UPDATE CDR Thomas R. Berry, RPh FDA, Investigator RAL-RP / ATL-DO.
FDA’s Pharmaceutical Inspectorate Robert Coleman National Expert Drug Investigator Food and Drug Administration.

FDA’s Pharmaceutical Inspectorate Robert Coleman National Expert Drug Investigator Food and Drug Administration.
Field Investigators: ADE Detectives. Section One Introduction to the Team and Their Roles.

Field Investigators: ADE Detectives. Section One Introduction to the Team and Their Roles.
FDA’s MedWatch Program Outreach to Healthcare Professionals and the Public n Managing the Risks of Medical Product Use.

FDA’s MedWatch Program Outreach to Healthcare Professionals and the Public n Managing the Risks of Medical Product Use.
Top Tactics for Maximizing GMP Compliance in Blue Mountain RAM Jake Jacanin, Regional Sales Manager September 18, 2013.

Top Tactics for Maximizing GMP Compliance in Blue Mountain RAM Jake Jacanin, Regional Sales Manager September 18, 2013.
FDA and Pharmaceutical Manufacturing Research Projects Jeffrey T. Macher Jackson A. Nickerson Co-Principal Investigators.

FDA and Pharmaceutical Manufacturing Research Projects Jeffrey T. Macher Jackson A. Nickerson Co-Principal Investigators.
Chapter 22 The Private Security Professional and Profession.

Chapter 22 The Private Security Professional and Profession.
Adverse Event Reports on Automatic External Defibrillators from 1996 - 2003 Oscar H Tovar MD and Beverly Gallauresi RN, MPH Food and Drug Administration.

Adverse Event Reports on Automatic External Defibrillators from Oscar H Tovar MD and Beverly Gallauresi RN, MPH Food and Drug Administration.
Trends in Occupational and Adult Lead Exposure in Wisconsin 1988 - 2005 By Henry Anderson, MD Monirul Islam, MD, PhD Wisconsin Division of Public Health.

Trends in Occupational and Adult Lead Exposure in Wisconsin By Henry Anderson, MD Monirul Islam, MD, PhD Wisconsin Division of Public Health.
Module 5 | Slide 1 of 22 January 2006 Sections 5 and 6 Basic Principles of GMP Complaints and Recalls.

Module 5 | Slide 1 of 22 January 2006 Sections 5 and 6 Basic Principles of GMP Complaints and Recalls.
FDA Recalls Risk Communication Advisory Committee David K. Elder Director, Office of Enforcement.

FDA Recalls Risk Communication Advisory Committee David K. Elder Director, Office of Enforcement.
United States Department of Agriculture Food Safety Inspection Service SALMONELLA SUBTYPING RESULTS IN RAW PRODUCTS FSIS Notice 27-10 6/3/2010 Policy Development.

United States Department of Agriculture Food Safety Inspection Service SALMONELLA SUBTYPING RESULTS IN RAW PRODUCTS FSIS Notice /3/2010 Policy Development.

Similar presentations

Ads by Google